Sohomoy

Liquid Biopsy and the Circulating Tumor Cell Market

2 min read
0
Comments
56
Views

Liquid biopsy is transforming cancer care, and circulating tumour cells are one of its most promising components. Unlike tissue biopsy — which is invasive, captures only a single location, and may be impossible to repeat frequently — liquid biopsy enables serial sampling, captures tumour heterogeneity across multiple sites, and can be performed repeatedly with minimal patient burden. CTCs are at the heart of this shift, and their isolation technologies are central to the circulating tumour cell market.

The market is being driven by the shift from tissue to liquid biopsy, growing demand for non-invasive monitoring, rising clinical trial adoption of CTC endpoints, and technological advances in CTC isolation. According to circulating tumor cell market research, liquid biopsy adoption is a key growth driver, supported by clinical evidence and technology. Growth is driven by the need for repeated, minimally invasive testing.

Innovation includes microfluidic CTC capture, label-free enrichment, and integrated multi-omic analysis.

Challenges include sensitivity, specificity, and cost.

Yet the trend is clear: liquid biopsy will continue to expand, and the market is expected to benefit substantially.

People Also Ask

Q: How is liquid biopsy different from tissue biopsy?
A: Liquid biopsy uses blood samples rather than tissue, enabling non-invasive, repeatable testing and capturing tumour heterogeneity across sites.

Q: What are the advantages of CTC-based liquid biopsy?
A: It is minimally invasive, allows serial monitoring, and can capture tumour evolution in real time.

Tags: #LiquidBiopsy #CTCIsolation #NonInvasiveTesting #CancerMonitoring #Microfluidics #MarketTrends